Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2009

View Archived Issues

SJL-01 exhibits safety and potent anti-leishmania activity in preclinical evaluation

Rohto claims novel collagen production-promoting peptides for RA

Novel nAChR modulators in early development at NeuroSearch

Amira Pharmaceuticals describes CRTH2 antagonists for respiratory disorders

Novel compounds for the treatment of glaucoma claimed by Allergan

FDA clears Agriflu seasonal influenza vaccine

Lorus Therapeutics reports results of phase II LOR-2040 trial in AML

Spectrum completes enrollment in phase III trial of apaziquone in bladder cancer

Novel 2,3-dioxygenase inhibitor disclosed by Incyte for cancer immunotherapy

3,4-DAP obtains FDA orphan drug status for Lambert-Eaton myasthenic syndrome

S*BIO presents its novel, potent dual PI3K/mTOR inhibitor SB-2312

Proacta reports data on its novel hypoxia-activated pan-HER inhibitor

EMEA grants Clinuvel the status of small and medium enterprise

Chronic sildenafil improves clinical outcomes in heart failure patients

Lp-PLA2 levels did not predict CVD risk in atorvastatin-treated diabetic subjects

Bavarian Nordic to file for market approval for Imvamune smallpox vaccine in Canada

Novartis claims Toll-like receptor agonists for the treatment of asthma

CB1 receptor antagonists described by sanofi-aventis for the treatment of obesity

EMD Serono receives refuse to file letter from FDA on cladribine NDA

Cytokine completes phase I trial of CPSI-2364

Novavax completes enrollment in phase IIa seasonal influenza vaccine study

Angiox approved in E.U. for additional indication

FDA approves Cymbalta for maintenance treatment of GAD

Lundbeck initiates clinical phase II Lu-AE-58054 trials in Alzheimer's disease

Stemline Therapeutics expands oncology program directed at cancer stem cells

PPD completes acquisition of BioDuro

Tripep completes phase I trial of ChronVac-C hepatitis C virus DNA vaccine